| | Publication Year | Title | Author(s) |
| 1 | 9-Dec-2013 | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. | Butts, Charles; Socinski, Mark A; Mitchell, Paul L R ; Thatcher, Nick; Havel, Libor; Krzakowski, Maciej; Nawrocki, Sergiusz; Ciuleanu, Tudor-Eliade; Bosquée, Lionel; Trigo, José Manuel; Spira, Alexander; Tremblay, Lise; Nyman, Jan; Ramlau, Rodryg; Wickart-Johansson, Gun; Ellis, Peter; Gladkov, Oleg; Pereira, José Rodrigues; Eberhardt, Wilfried Ernst Erich; Helwig, Christoph; Schröder, Andreas; Shepherd, Frances A |
| 2 | 18-Nov-2013 | Lung cancer in Victoria: are we making progress? | Mitchell, Paul L R ; Thursfield, Vicky J; Ball, David L; Richardson, Gary E; Irving, Louis B; Torn-Broers, Yvonne; Giles, Graham G; Wright, Gavin M |
| 3 | 16-Oct-2013 | Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. | Liew, Mun Sem; Sia, Joseph; Starmans, Maud H W; Tafreshi, Ali; Harris, Sam; Feigen, Malcolm; White, Shane C; Zimet, Allan; Lambin, Philippe; Boutros, Paul C; Mitchell, Paul L R ; John, Thomas |
| 4 | 23-Jul-2013 | The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. | John, Thomas ; Starmans, Maud H W; Chen, Yao-Tseng; Russell, Prudence A; Barnett, Stephen A ; White, Shane C; Mitchell, Paul L R ; Walkiewicz, Marzena; Azad, Arun A; Lambin, Philippe; Tsao, Ming-Sound; Deb, Siddhartha; Altorki, Nasser; Wright, Gavin; Knight, Simon R ; Boutros, Paul C; Cebon, Jonathan S |
| 5 | 23-May-2011 | Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. | Mitchell, Paul L R ; Broad, Adam; Rosenthal, Mark A; Galettis, Peter; Abraham, Rick; Burns, Ivon; Clarke, Stephen; Milner, Alvin; Diiulio, Juliana; Links, Matthew |
| 6 | 28-Mar-2009 | Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. | Lee, S T; Ghanem, M; Herbertson, R A; Berlangieri, Salvatore U ; Byrne, Amanda J; Tabone, K; Mitchell, Paul L R ; Knight, Simon R ; Feigen, Malcolm; Scott, Andrew M |
| 7 | 21-May-2007 | Prevalence of occult metastatic disease in patients undergoing 18F-FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules. | Lee, S T; Berlangieri, Salvatore U ; Poon, A M T; Mitchell, Paul L R ; Pathmaraj, K ; Tabone, K; Byrne, Amanda J; O'Keefe, Graeme J; Knight, Simon R ; Clarke, C Peter; Scott, Andrew M |
| 8 | 5-May-2005 | Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer. | Yap, Kelvin K; Byrne, Amanda J; Berlangieri, Salvatore U ; Poon, Aurora M T ; Mitchell, Paul L R ; Knight, Simon R ; Clarke, Peter C; Harris, Anthony H; Tauro, Andrew; Rowe, Christopher C ; Scott, Andrew M |
| 9 | 1-Jul-2004 | Positron emission tomography scanning in the assessment of patients with lymphoma. | Foo, S S; Mitchell, Paul L R ; Berlangieri, Salvatore U ; Smith, C L; Scott, Andrew M |
| 10 | 1-May-2003 | A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. | Scott, Andrew M ; Wiseman, Greg; Welt, Sydney; Adjei, Alex; Lee, Fook-Thean; Hopkins, Wendie; Divgi, Chaitan R; Hanson, Lorelei H; Mitchell, Paul L R ; Gansen, Denise N; Larson, Steven M; Ingle, James N; Hoffman, Eric W; Tanswell, Paul; Ritter, Gerd; Cohen, Leonard S; Bette, Peter; Arvay, Lisa; Amelsberg, Andree; Vlock, Dan; Rettig, Wolfgang J; Old, Lloyd J |